We investigated the effect on outcome of measurable or minimal residual disease (MRD) status after each induction course to evaluate the extent of its predictive value for acute myeloid leukemia (AML) risk groups, including NPM1 wild-type (wt) standard risk, when incorporated with other induction response criteria.
We investigated the effect on outcome of measurable or minimal residual disease (MRD) status after each induction course to evaluate the extent of its predictive value for acute myeloid leukemia (AML) risk groups, including NPM1 wild-type (wt) standard risk, when incorporated with other induction response criteria.
Methods
As part of the NCRI AML17 trial, 2,450 younger adult patients with AML or high-risk myelodysplastic syndrome had prospective multiparameter flow cytometric MRD (MFC-MRD) assessment. After course 1 (C1), responses were categorized as resistant disease (RD), partial remission (PR), and complete remission (CR) or complete remission with absolute neutrophil count , 1,000/mL or thrombocytopenia , 100,000/mL (CRi) by clinicians, with CR/CRi subdivided by MFC-MRD assay into MRD+ and MRD2. Patients without high-risk factors, including Flt3 internal tandem duplication wt/2NPM1-wt subgroup, received a second daunorubicin/cytosine arabinoside induction; course 2 (C2) was intensified for patients with high-risk factors.
Results
Survival outcomes from PR and MRD+ responses after C1 were similar, particularly for good-to standard-risk subgroups (5-year overall survival [OS] , 27% RD v 46% PR v 51% MRD+ v 70% MRD2; P , .001). Adjusted analyses confirmed significant OS differences between C1 RD versus PR/MRD+ but not PR versus MRD+. CRi after C1 reduced OS in MRD+ (19% CRi v 45% CR; P = .001) patients, with a smaller effect after C2. The prognostic effect of C2 MFC-MRD status (relapse: hazard ratio [HR], 1.88 [95% CI, 1.50 to 2.36], P , .001; survival: HR, 1.77 [95% CI, 1.41 to 2.22], P , .001) remained significant when adjusting for C1 response. MRD positivity appeared less discriminatory in poor-risk patients by stratified analyses. For the NPM1-wt standard-risk subgroup, C2 MRD+ was significantly associated with poorer outcomes (OS, 33% v 63% MRD2, P = .003; relapse incidence, 89% when MRD+ $ 0.1%); transplant benefit was more apparent in patients with MRD+ (HR, 0.72; 95% CI, 0.31 to 1.69) than those with MRD2 (HR, 1.68 [95% CI, 0.75 to 3.85]; P = .16 for interaction).
Conclusion
MFC-MRD can improve outcome stratification by extending the definition of partial response after first induction and may help predict NPM1-wt standard-risk patients with poor outcome who benefit from transplant in the first CR.
INTRODUCTION
In acute myeloid leukemia (AML), failure to achieve morphologic complete remission (CR) after a first cycle of induction in previously untreated patients is an established independent prognostic factor from earlier studies. [1] [2] [3] Thus, morphologic response at this time point is often incorporated with genetic and pretreatment clinical parameters to guide further therapy, 4 including second induction courses, choice of consolidation, and whether intensification from allogeneic stemcell transplantation (SCT) may be appropriate in otherwise intermediate-risk patients. Despite morphologic response criteria being standard, a different approach for measuring response has been proposed 5, 6 owing to the independent prognostic value from measurable or minimal residual disease (MRD) assays when discrepant with morphology, 7-9 or in CR 10-12 and the equivalent poor outcomes between MRD positivity and active-disease premyeloablative SCT. 13, 14 Studies have shown the prognostic value of MRD monitoring by polymerase chain reaction (PCR) for patients with validated molecular targets, usually after two courses of chemotherapy. 11, 12, 15 Multiparametric flow cytometry MRD (MFC-MRD) may identify, as early as after course 1 (C1), patients with a poorer response despite achieving CR and is an assay that can be applied across AML genetic subgroups. 12, [16] [17] [18] [19] [20] There are, however, insufficient data to ascertain the relative prognostic effect of MFC-MRD positivity in CR post-C1 compared with morphologic active disease; it is feasible that the outcomes of patients with detectable MRD resemble those of refractory patients who achieve the cytoreduction criteria for a morphologic partial remission (PR). 21, 22 Evaluating this will help refine which response categories are the most useful prognostic surrogate end points to assess effectiveness of the first induction course.
It is also uncertain for patients who complete a second chemotherapy course whether the quality of response after C1, with inclusion of MFC-MRD assessment, adds prognostic information to CR-MRD status after course 2 (C2). The value of MFC-MRD status to differentiate outcome at either time point is likely to be heterogeneous between established risk subgroups due to disease, treatment, and assay factors, but the extent of this has not been established.
Treatment decisions, including predicting the benefit of SCT, are particularly challenging for the standard-risk subgroup. MFC-MRD assays are most likely to influence therapeutic choices for NPM1-wild type (wt) patients of standard risk, following data indicating postinduction reverse transcriptase, quantitative PCR (RT-qPCR) of blood-mutated transcripts reliably predicts outcome for patients with NPM1 mutation. 23, 24 Thus, there is a specific need to define the usefulness of MFC-MRD for risk stratification in this subgroup.
In this study, we aimed to determine the prognostic effect of MFC-MRD measurement incorporated into response assessment after induction courses for the different risk subgroups, including NPM1-wt patients at standard risk, in a large cohort of younger patients with AML who had undergone intensive treatment in the National Cancer Research Institute (NCRI) AML17 trial.
METHODS

Patients
Patients were enrolled in the NCRI AML17 trial (ISRCTN Registry No. 55675535) from April 6, 2009 , to December 31, 2014 . A list of treatments is provided in Appendix Fig. A1 (online only).
The AML17 protocol was designed primarily for younger patients, generally age , 60 years. Patients with high-risk myelodysplastic syndrome, which was defined as . 10% marrow blasts at diagnosis, and secondary AML were eligible. Patients with acute promyelocytic leukemia were not included in this MRD study. After first induction, patients were defined by risk of relapse, using a validated score comprising cytogenetics, WBC count, age, secondary disease, morphologic response to C1 25, 26 and FLT-3 internal tandem duplication(ITD)/NPM1 mutation status.
Morphologic-based response criteria were as follows: (1) CR, , 5% blasts in a cellular bone marrow with count recovery, CRi if 5% blasts but best response was with neutropenia , 1,000/mL or thrombocytopenia , 100,000/mL; (2) partial remission (PR), decrease of pretreatment bone marrow blast percentage by at least 50% to 5% to 15% in a cellular marrow (hematologic recovery not required) 1 ; and (3) resistant disease (RD), . 15% marrow blasts (patients surviving at least 7 days after completion of treatment). Responses were classified by centers.
Patients designated as favorable or at standard risk received the second daunorubicin/cytosine arabinoside course and were then randomized to receive either 1 or 2 courses of high-dose cytosine arabinoside. High-risk patients were offered a randomization between FLAG-Ida or daunorubicin/clofarabine with the intention of eventually proceeding to allogeneic stem-cell transplantation (SCT). FLT3-ITD mutant patients were directed to the lestaurtinib randomization until 2012.
The trial was sponsored by Cardiff University, approved by Wales-REC3 and conducted in accordance with the Declaration of Helsinki.
Multiparameter Flow Cytometry Detection of MRD
Samples for multiparameter flow cytometry (MFC)-MRD were requested at baseline (bone marrow and/or blood) and following each course (bone marrow). A summary of sample logistics and processing is provided in the Data Supplement. MFC-MRD analysis was performed centrally, using standardized gating strategy that screened for "differentfrom-normal" leukemia-associated-immunophenotypes (LAIPs) on blasts pretreatment and tracked these (approximately 0.02% to 0.05% sensitivity thresholds) but also applied the different-to-normal approach in follow-up samples to detect changes in blast LAIPs (approximately 0.05% to 0.1% sensitivity threshold). In this study, only samples for which there were pretreatment LAIPs to monitor could be reported as MFC-MRD negative, whereas samples with any level of MRD detected above a diagnostic LAIP or different-from-normal follow-up LAIP threshold were reported as MFC-MRD positive. Clinicians were not informed of MFC-MRD results.
Statistical Analysis
All end points were based on the revised criteria of the International Working Group for Diagnosis.
21 Survival percentages were calculated using the Kaplan-Meier method with cumulative incidence of relapse calculated using competing-risks methodology. Baseline characteristics were compared using x 2 or Mantel-Haenszel tests, with continuous variables compared using the Wilcoxon rank-sum test. Time-to-event outcomes were compared using log-rank tests and Cox regression. Outcomes are reported as effect sizes with 95% confidence intervals; significance was set at P , .05. Stratified analyses used stratified log-rank tests and are displayed as forest plots with tests for interaction using standard methodology. 27 Comparison of transplantation versus not was analyzed using the method of Mantel and Byar to mitigate immortal time bias. Median followup for survival was 39.0 months (range, 1.0 to 80.5 months).
RESULTS
Induction Response by Morphology and MFC-MRD: Patient Characteristics
Between 2009 and 2014, 6,539 samples (bone marrow [BM] or peripheral blood at diagnosis, BM post-treatment courses) from 2,450 patients with non-acute promyelocytic leukemia recruited to AML17 were prospectively analyzed for MFC-MRD (Appendix Fig  A2, online only) . Among patients in CR post-C1, the presence of MRD data were associated with secondary AML, and the absence of an NPM1 mutation (reflecting the prioritizing of BM for RT-qPCR monitoring of NPM1 mutations 23 during the second phase of the trial); survival at 5 years was 52% (with MRD data) versus 50% The clinical characteristics of patients according to response post-C1 and MRD status for patients in CR/CRi post-C1 or C2 are listed in Table 1 . There was a significant association between responses post-C1 or C2 and cytogenetic group; however, count recovery post-C1 was not significantly associated with MRD after either course.
Outcome Comparison for Morphologic Response and MFC-MRD Status After C1
We evaluated overall survival (OS) by C1 response status. Five-year OS for all enrolled in AML17 excluding early deaths was 52% for those achieving CR/CRi versus 31% for refractory patients (P , .001). MRD status in CR/CRi versus PR or RD further differentiated 5-year survival outcomes ( Fig 1A) . A PR or MRD+ response gave intermediate survival at 5 years. Survival rates appeared equivalent between these two responses for the patients at good or standard risk; 5-year OS for MRD2 versus MRD+ versus PR versus RD were 63% versus 44% versus 35% versus 24%, respectively, for all patients; 70% versus 51% versus 46% versus 27%, respectively, when patients at poor risk were excluded ( Fig 1B) ; and 66% versus 49% versus 46% versus 30%, respectively, for standard risk alone (P , .001 for all analyses; Fig 1C) . Similar results were observed for survival censored at SCT (Fig 1D; Fig A3A , online only) and also for NPM1-wt patients at standard risk (Fig A3B and A3C) .
Adjusted analyses confirmed significant survival differences between RD and PR/MRD+ but not between PR and MRD+ for patients at good or standard risk (RD v PR/MRD+: OS HR, 2.28 [95% CI, 1.38 to 3.75]; P , .001; PR vs MRD+: HR, 1.32; P = .4) and for NPM1-wt patients at standard risk (RD v PR/MRD+: OS HR, 2.13 [95% CI, 1.21 to 3.75]; P = .008; PR vs MRD+: HR, 1.18, P = .6). Results were similar when censored at SCT ( OS for patients at standard risk censored at allogeneic stem-cell transplantation. CR, complete remission; CRi, complete remission with absolute neutrophil count , 1,000/mL or thrombocytopenia , 100,000/mL; MRD, measurable residual disease; PR, partial remission; RD, resistant disease.
Thus, the prognostic effect from morphologic response criteria after first induction was restricted to RD in the good and standard-risk subgroups when MFC-MRD status was incorporated into response assessment.
Only 25 patients were refractory by morphology post-C1 but MRD2 (n = 22 PR; n = 3 RD) with 61% 3-year and 49% 5-year OS. Seven of 577 MRD+ patients were in morphologic CR but had $ 5% aberrant blasts by MFC (range, 5.4% to 38%); six died within 2 years, with one patient alive at 58.6 months.
Relative Prognostic Effect of MFC-MRD After C1 and C2 by Genetic/Risk Score Subgroup
In AML17, patients received two courses of induction regardless of remission status after C1, but C2 differed for patients designated as poor risk by trial risk score. Analyses of survival and relapse by MFC-MRD status of patients with disease in CR/CRi for C1 (n = 1,010) and C2 (n = 803) were performed stratified by cytogenetic 28 and trial risk subgroups (Fig 2; Appendix Fig A4, online only) to investigate the relative prognostic effect from clearance of blasts below MFC-MRD detection threshold at either of these response assessment time points. There was some evidence that the benefit from MFC-MRD negativity on OS was lower in patients at poor risk compared with other subgroups with the NCRI AML17 treatment schedule (P for test for trend = .01 for C1; P = .05 for C2 
Outcomes of Combined C1 Response Status and C2 MFC-MRD Status
In patients with response/MFC-MRD data for both C1 and C2 time points (n = 693), C2 MFC-MRD positivity remained significant on OS and relapse when adjusting for C1 response (5-year survival: HR, 1.79 [95% CI, 1.38 to 2.32], P , .001; relapse: HR, 1.52 [95% CI, 1.18 to 1.96], P = .001; Fig 3) . A total of 24 patients converted from C1 MRD2 to C2 MRD+, with a particularly poor prognosis (n = 15 relapses; n = 13 deaths); one had adverse risk cytogenetics and five had Flt3-ITD mutations (Appendix Table A1 ). Patients who were MRD2 at both C1 and C2 had the best outcome (n = 224; n = 76 relapses; n = 58 deaths); of these, 80.8% were at good or standard risk and 26.3% were NPM1-wt patients at standard risk (Appendix Table A2 ).
MRD Status Combined With Peripheral Count Recovery
We examined the additional prognostic effect of combining MRD status with response by peripheral count recovery post-C1 and C2 (Appendix Table A3 ). The frequencies of CRi as best response in the total cohort were similar in MRD+ versus MRD2 patients post-C1 (9.3% v 9.6%) and C2 (13.1% v 12.0%); CRi frequencies were not relatively increased in the NPM1-wt standard-risk subgroup. C1 CRi was associated with significantly decreased 5-year OS for total (39% v 53%; P = .002) and in MRD+ (19% v 45%; P = .001), but not for MRD2 patients. MRD+ NPM1-wt patients at standard risk in CRi also had a lower OS at 5 years (25% v 48%; P = .4), although difference was not significant. The effect of CRi versus CR was smaller post-C2, although outcomes were still worse in CRi/MRD+ patients. The reduced survival associated with CRi was not due to increased relapse.
Outcome by MFC-MRD Status for NPM1-wt Patients at Standard Risk
Because it is possible that the most appropriate MFC-MRD cutoff level for discriminating outcome may differ among AML genetic subgroups, we compared the 5-year cumulative incidence of relapse for C1 MRD2 versus MRD+ , 0.1% versus MRD+ $ 0.1% by our assay in core binding factor (CBF)-AML and NPM1-mutated as well as NPM1wt standard-risk patients. For patients with CBF-AML and NPM1 mutation, post-C1 MRD+ at any level (, 0.1% or $ 0.1%) significantly increased relapse (Appendix Fig  A5, online only) . However, in the NPM1-wt standard-risk subgroup, low-level MRD+ (, 0.1%) post-C1 did not alter relapse risk compared with MRD2 but was associated with a higher cumulative incidence of relapse (CIR) when detected post-C2 (Fig 4A) . MRD+ levels of $ 0.1% detected in 35% and 13% NPM1-wt patients at standard risk post-C1 and post-C2, respectively, predicted a high probability of relapse (C1 3-year CIR, 68%; C2 CIR, 89%). MRD status after second induction was also significantly prognostic for survival: 33% for any level of MRD positivity versus 63% for MRD2 at 5 years (3 years, 47% v 69%; P = .003; Fig 4B) .
Of the 204 NPM1-wt patients at standard risk who had C2 MRD data, 83 had an allograft (n = 44 in first CR: n = 29 MRD2 and n = 15 MRD+). When survival was censored at any SCT, rates of 5-year OS were 35% versus 88% (3 years, 47% v 88%; P , .001; Appendix Fig A6, online only) .
We next investigated the effect of SCT in first CR according to C2 MRD status in Mantel-Byar analyses. Although numbers were small, results suggested that transplant might be considered in MRD+ (HR, 0.72; 5% CI, 0.31 to 1.69) but not MRD2 patients (HR, 1.68 [95% CI, 0.75 to 3.85] ; P for interaction = .16; Fig 4C) .
DISCUSSION
Response to induction therapy is a powerful prognostic indicator in AML. There are, however, differing practices for the implementation of technologies that measure residual leukemia to assess response. Flow cytometry is often used to support the definition of CR by morphology; those centers with access to experienced laboratories, including some trial groups, have extended its use to define CR without MRD.
5 It has been reported that outcomes after myeloablative SCT for patients with pretransplant MFC-MRD , 5% resemble those with at least 5% blasts by morphology.
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This and the similar event-free survival observed in approximately 80 pediatric patients with MRD positivity after first induction, whether , 5% or $ 5% blasts by morphology, 7 suggest that dichotomizing patients by a 5% blast CR cutoff fails to capture some prognostic information. Our results confirm this. By incorporating MFC-MRD with established response criteria of PR and RD, distinct prognostic groups for 5-year survival emerge after the first jco.org jco.org three post-C1 response categories could be proposed: RD, PR (MFC-MRD+ whether below or above 5% blast threshold), and CR/CRi without MRD. CRi was an independent risk factor to MRD in a study that included patients with relapsed or refractory AML and differing induction intensities. 29, 30 From our data, outcomes for patients newly diagnosed with AML achieving negative MRD are equivalent between CRi and CR after a single standard induction. However, the relatively few patients in our cohort (4.8%) with both CRi and MRD positivity after C1 had as poor survival (OS, 19% for all;, 25% for NPM1-wt patients at standard risk) as patients with RD.
For those completing a second induction with a CR/CRi, MRD status after C2 increased prognostic discrimination. Although sample attrition bias may limit analyses comparing time points, MRD negativity post-C2 improved outcome overall even when adjusting for slower blast clearance by C1 response. This differs from our previous results in older adults 17 and might reflect the better treatment tolerance and mutation profiles of younger adults. However, after the second daunorubicin/cytosine arabinoside induction, approximately 33% of patients at standard risk and approximately 34% of NPM1-wt patients at standard risk in CR/CRi had persistent BM MRD by our assay. Whether detectable MFC-MRD after completion of conventional induction is a sufficiently specific prognostic surrogate to guide therapy has been debated. The postconsolidation time point was more informative in the GIMEMA (Gruppo Italiano Malattie Ematologiche dell'Adulto) study for a cohort of which approximately 70% had intermediate cytogenetics. 31, 32 This suggests that in a proportion of those with postinduction MRD positivity, consolidation may confer a favorable outcome by additional MFC-MRD clearance (although it is of note that for some younger adults in the GIMEMA trials, the induction/consolidation regimen comprised two courses in total). Genetic profile, treatment intensity, and the later effects of any transplant may also modify interpretation and utility of MFC-MRD to inform postremission therapy. Our data are consistent with this because the prognostic effect as well as best MFC-MRD cutoff level differed between AML risk groups; MRD status appeared less discriminatory in the patients at poor risk. Importantly, however, in the NPM1-wt standard-risk subgroup, detectable MFC-MRD at $ 0.1% early in treatment was associated with significantly higher relapse rates (89% after C2). The falsenegative 50% CIR observed for postinduction MFC-MRD negative patients in the NPM1-wt, standard-risk subgroup could reflect MFC-MRD sensitivity limitations, although a similar CIR was observed for patients with DNTM3A/NPM1 mutations who were MRD negative by NPM1-mutated transcript RT-qPCR. 23 Exploratory analyses could not identify any significant clinical parameters that predicted MRD2 relapses. Longitudinal, broad molecular studies may disclose whether increased preleukemic instability reinitiating AML 33,34 or persistence of pretreatment minor or major leukemic clones 35, 36 contributes to these falsenegative relapse risks. Notwithstanding, NPM1-wt patients at standard risk who achieved MRD negativity post-C2 had significantly better survival rates. Because their survival rate increased to 88% when censored for transplant, there is the possibility that transplant in first remission could be avoided in this subset. The Mantel-Byar analysis supports this with some evidence of interaction, although this should be interpreted cautiously because of the small number of patients and the interaction was not significant. Transplant decisions have mainly been arbitrary in this subgroup, with no accepted approach to distinguish those patients likely to be cured with chemotherapy alone (or those whose response is likely to be successful after salvage therapy if they do relapse) from those who benefit from transplantation in first remission or potentially experimental therapy. Our results suggest that allogeneic transplant in first remission could be directed to those who are MRD+ rather than MRD2. This is the first indication that MRD status might have utility in directing therapy for NPM1-wt patients at standard risk despite their molecular heterogeneity. Large patient data sets likely requiring collaborative efforts will determine whether integrating MFC-MRD status with genomic profiles 37,38 further informs outcome prediction.
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